We have vast expertise in in vitro human brain cell models (Park et al Nature Protocols, 17:190-221, 2022) aligned with strong molecular pharmacology capabilities (Smyth et al, Commun Biol. 2022;5(1):235; Jansson et al, Commun Biol. 2021;4:260) to undertake drug mode of action studies.